Platelet aggregation for diagnosing acute kidney transplant rejection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot observational study longitudinally measures platelet aggregation and activation markers in adult kidney transplant recipients before transplant and at protocol biopsies 3 and 12 months after transplant, and in patients undergoing indication biopsies for suspected graft dysfunction. Platelet function is measured by optical aggregometry, flow-cytometric P-selectin (CD62-P) expression, and soluble P-selectin levels. These platelet parameters are correlated with biopsy histology, donor-specific antibodies, metabolic data, and clinical outcomes. The goal is to determine whether platelet activation profiles can identify cellular or antibody-mediated rejection and support development of a non-invasive diagnostic tool.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* adult patients (≥18 years)
* primary kidney transplantation
* living / deceased donor kidney transplantation
* ability and consent to participate

Exclusion Criteria:

* non-adult patients
* secondary / tertiary kidney transplantation
* antiplatelet therapy
* patients unable to provide informed consent

Where it's running

• Transplant-Nephrology Department, University Hospital Martin
  Martin, Slovakia Recruiting

Study contacts

• Study coordinator: Timea Blichova, MD
• Email: tc@unm.sk
• Phone: +421434203184

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Belimumab to mobilize memory B cells to help delistings for highly sensitized kidney transplant candidates

  A short belimumab course is being tested to see if it can reveal memory B cells that target donor HLAs, helping to decide which donors to exclude and potentially speed up getting a transplant for highly sensitized patients.

  Recruiting Phase 2 Leiden University Medical Center · Leiden · NCT07539857

• Frexalimab versus tacrolimus to prevent kidney transplant rejection

  This trial will test whether frexalimab injections given for up to five years work as well and are as safe as tacrolimus capsules at preventing rejection in adults getting their first kidney transplant who have low-to-moderate immune risk.

  Recruiting at 73 sites Phase 2/3 Sanofi · San Francisco, California and 72 other locations · NCT07412470

• Donor-Derived Cell-Free DNA Test for Monitoring Kidney Transplants

  This test will try whether a blood-based donor-derived cell-free DNA (dd-cfDNA) assay can detect rejection in adults who have received a kidney transplant.

  Recruiting at 6 sites Insight Molecular Diagnostics · Los Angeles, California and 9 other locations · NCT07060716

• CRISPR-edited donor kidney transplant to reduce rejection risk

  This trial will see if donor kidneys edited with CRISPR to turn off key HLA genes can lower rejection in adults with end-stage kidney disease receiving transplants.

  Recruiting Phase 1/2 American Organ Transplant and Cancer Research Institute LLC · Beijing, Changping · NCT07053462

• Tocilizumab plus standard therapy for chronic antibody-mediated rejection after kidney transplant

  This trial will try adding tocilizumab to standard treatment (plasmapheresis, IVIG, and rituximab) to see if it helps people with chronic active antibody-mediated rejection of a kidney transplant.

  Recruiting Shahid Beheshti University of Medical Sciences · Tehran · NCT07006532

• Treating antibody-mediated kidney transplant rejection with carfilzomib and belatacept

  We will test whether adding carfilzomib and belatacept to steroids and standard immunosuppression can safely reduce antibody-mediated injury in kidney transplant recipients with donor-specific antibodies.

  Recruiting at 9 sites Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · Birmingham, Alabama and 10 other locations · NCT06918990

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.